NVS Apr 2023 100.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:46PM EDT. Market open.
Loading interactive chart…
- Zacks
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
- Zacks
The Zacks Analyst Blog Highlights Johnson & Johnson, Toyota Motor, Infosys, Novartis and Equinix
Johnson & Johnson, Toyota Motor, Infosys, Novartis and Equinix are part of the Zacks top Analyst Blog.
- GlobeNewswire
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walkingTo date, more than 3,000 children with spinal muscular atrophy have been treated with Zolgensma across clinical trials, managed access programs and in the commercial setting1 Additionally, children wi
© 2023 Yahoo. All rights reserved.
